Figure 2.

Viability of huh7 cancer cell under sham, DOX, and B307+DOX treatments.

Notes: (A) The relative viabilities of Huh7 cancer cells were not changed under B307 treatment at doses of 10–160 mg/mL. (B) The relative viabilities of Huh7 cancer cells were significantly reduced under DOX treatment but were not significant between DOX only and DOX+B307 treatment. Each treatment was repeated at least six times. Values are mean ± SEM (**P<0.01, two-way ANOVA followed by a Student–Newman–Keuls multiple comparisons posttest).

Abbreviations: DOX, doxorubicin; MW, molecular weight; SEM, standard error of the mean; ANOVA, analysis of variance.